MDT

82.53

-3.2%↓

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

MDT

82.53

-3.2%↓

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

MDT

82.53

-3.2%↓

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

MDT

82.53

-3.2%↓

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

MDT

82.53

-3.2%↓

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

4.14 -2.59

Buy Sell

Overview

Share price change

24h

Current

Min

4.11

Max

4.25

Key metrics
By Trading Economics
Income	466K -27M
Sales	2M 15M
Profit margin	-178.834
Employees	141
EBITDA	-2M -29M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+246.81% upside

Dividends
By Dow Jones
Next Earnings	4 maj 2026

Market Stats
By TradingEconomics
Market Cap	24M 252M
Previous open	6.73
Previous close	4.14

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

21 kwi 2026, 23:27 UTC

Major News Events

BHP Expects Annual Copper Output in Upper Half of Guidance, Finishes China Iron-Ore Negotiations

21 kwi 2026, 23:27 UTC

Hot Stocks

Stocks to Watch: Sonoco Products, Adobe, Manhattan Associates, Target Hospitality

21 kwi 2026, 23:02 UTC

Earnings

Correction to Capital One Financial 1Q Earnings Article

21 kwi 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 kwi 2026, 23:47 UTC

Market Talk

Nikkei May Decline as Hopes for U.S.-Iran Peace Talks Fade

21 kwi 2026, 23:36 UTC

Market Talk

Major News Events

Market Talk Roundup: Latest on U.S. Politics

21 kwi 2026, 23:36 UTC

Market Talk

Major News Events

Gold Edges Higher After Trump Says U.S. Will Extend Cease-Fire Deadline -- Market Talk

21 kwi 2026, 23:32 UTC

Earnings

America Movil 1Q EBITDA MXN94.5B, Up 3.8% on Year >AMX

21 kwi 2026, 23:30 UTC

Earnings

America Movil 1Q Rev MXN236.84B, Up 2.1% on Year >AMX

21 kwi 2026, 23:28 UTC

Earnings

America Movil 1Q Net MXN23.4B Vs. Net MXN18.7B >AMX

21 kwi 2026, 23:16 UTC

Major News Events

Ampol Entered 2Q With Hedge Book Positioned to Mitigate Volatility

21 kwi 2026, 23:15 UTC

Major News Events

Ampol Entered 2Q With Broad-Based Momentum

21 kwi 2026, 23:15 UTC

Major News Events

Ampol: Suitable Crudes for Lytton Remain Available in Market

21 kwi 2026, 23:14 UTC

Major News Events

Ampol: Crude Supplies Secured Into July

21 kwi 2026, 23:14 UTC

Major News Events

Ampol: Fuel Supplies Secured Until at Least End of May

21 kwi 2026, 23:13 UTC

Major News Events

Ampol: Well Placed for Crude, Product Supply Prior to Iran Conflict

21 kwi 2026, 23:13 UTC

Major News Events

Ampol 1Q Lytton Refinery Production 1.43 Billion Liters

21 kwi 2026, 23:12 UTC

Major News Events

Ampol 1Q Lytton Refiner Margin US$25.45/Bbl

21 kwi 2026, 22:54 UTC

Market Talk

Sell America Trade Could Gain Momentum If Fed Uncertainty Unresolved -- Market Talk

21 kwi 2026, 22:49 UTC

Major News Events

BHP 3Q Average Realized Energy Coal Price $105.61/Ton, Up 10% On-Quarter

21 kwi 2026, 22:49 UTC

Major News Events

BHP 3Q Average Realized Steelmaking Coal Price $226.76/Ton, Up 15% On-Quarter

21 kwi 2026, 22:48 UTC

Major News Events

BHP 3Q Average Realized Iron Ore Price $85.35/Ton, Flat On-Quarter

21 kwi 2026, 22:48 UTC

Acquisitions, Mergers, Takeovers

Alliance Portfolio Is Comprised of Five Plants: Batavia, Hillburn, Massena, Shoemaker and Sterling

21 kwi 2026, 22:48 UTC

Major News Events

BHP 3Q Average Realized Copper Price $5.86/Pound, Down 1% On-Quarter

21 kwi 2026, 22:48 UTC

Acquisitions, Mergers, Takeovers

PowerTransitions to Buy 323 MW of Power Generation Assets in New York State From Alliance Energy Group

21 kwi 2026, 22:46 UTC

Major News Events

BHP: Has Concluded Iron Ore Sales Contract Negotiations With China Mineral Resources Group

21 kwi 2026, 22:45 UTC

Major News Events

BHP: Pampa Norte Production Down on Ore Complexity, Variation; Declining Grades

21 kwi 2026, 22:45 UTC

Major News Events

BHP: Escondida Concentrator Investment Estimated Between $4.4 Billion-$5.9 Billion

21 kwi 2026, 22:44 UTC

Major News Events

BHP: Escondida Concentrator Project Seen Facing FID in 2027-28

21 kwi 2026, 22:42 UTC

Major News Events

BHP CEO: Centralized Procurement, Low-cost Operations Help Buffer Industry Wide Cost Pressures

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

246.81% upside

12 Months Forecast

Average 14.67 USD 246.81%

High 25 USD

Low 8 USD

Based on 8 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.